Close Menu

KRAS Biomarkers

News and reporting on KRAS biomarkers.

Although a record number of new precision oncology drugs came to market, the pandemic further exposed access gaps that the field is focused on mitigating.

Ikena will use the funding to advance its TEAD inhibitor into human trials and to pursue a preclinical program targeting KRAS signaling.

If approved, the drug would be the first targeted therapy available to treat patients with NSCLC harboring KRAS G12C mutations.

The Roche subsidiary will take over development of RLY-1971 and study it in combination with other drugs, such as its KRAS G12C inhibitor GDC-6036.

The trial will evaluate VS-6766 as a monotherapy or together with defactinib in ovarian cancer patients, including those with KRAS mutations.

The Swedish company will use the funds to grow its pipeline of antibodies to treat metastatic cancer and other diseases with the help of its Abiprot platform.

The Phase I trial will assess BBP-398's safety and anti-tumor activity in cancers with MAPK signaling pathway genetic mutations, including mutations in RAS genes.

A Phase I study used a less toxic dosing schedule that yielded encouraging response rates in patients with difficult-to-treat KRAS-mutated cancers.

The company presented on the preliminary activity of RMC-4630 combined with Cotellic and said it is studying the SHP2 inhibitor alongside an AstraZeneca drug.

The company said data from the Phase II portion of the CodeBreak-100 study in KRAS-mutated lung cancer patients was positive and may be registrational.